• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Sanofi-Aventis

Sanofi, Voluntis ink deal for digital insulin management system for T2D

March 14, 2017 By Sarah Faulkner

Sanofi, Voluntis ink deal for digital insulin management system for T2D

Sanofi (NYSE:SNY) and Voluntis said today that the groups inked a non-exclusive agreement to bring digital insulin management systems for Type II diabetes to the U.S. and several European countries. The companies 1st established in alliance in 2011, developing a mobile phone application that was designed to improve decision-making and self-management of patients with Type II […]

Filed Under: Diabetes, Featured, Patient Monitoring, Wall Street Beat Tagged With: Sanofi-Aventis, Voluntis

How Sanofi blew its chance with Actelion

February 16, 2017 By Sarah Faulkner

How Sanofi blew its chance with Actelion

Days before entering into exclusive takeover negotiations with Johnson & Johnson (NYSE:JNJ), Actelion (VTX:ATLN) was reportedly fielding an offer from Sanofi (NYSE:SNY). But the Swiss biotech eventually agreed to go with J&J’s $30 billion bid in an all-cash deal at the end of January. Actelion accepted the U.S. healthcare giant’s offer because it provided more certainty, Reuters reported today. The prospectus […]

Filed Under: Featured, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson, Pfizer Inc., Sanofi-Aventis

Collecting purposeful data in the era of connected health devices

February 16, 2017 By Sarah Faulkner

Collecting purposeful data in the era of connected health devices

Connectivity, one of the newest buzzwords in the medical device lexicon, is becoming more and more integral to device design and development. Research shows that connected health devices can improve patient outcomes by increasing adherence and reducing dosing variability. Mark David Tuckwell, head of electronics, software & systems at Sagentia, says connected device can also provide crucial information to help […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Adherium, Baxter International, Becton Dickinson, Companion Medical, GlaxoSmithKline plc, Propeller Health, Sagentia, Sanofi-Aventis

Early collaboration is key in drug-device development, experts say

February 15, 2017 By Sarah Faulkner

Industry leaders talk partnerships, collaboration in drug delivery

While pharmaceutical companies and medical device firms know that working together is a vital part of doing business, they “live in 2 different world in many ways,” Minnetronix co-founder Dirk Smith said last week at the annual Drug Delivery Partnerships conference. From development timelines to regulatory approval pathways, it can sometimes seem like pharma and medtech companies are […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Baxter International, Becton Dickinson, GlaxoSmithKline plc, Minnetronix, Sanofi-Aventis

Nordisk tumbles on lowered outlook

February 2, 2017 By Sarah Faulkner

Novo Nordisk

Shares in Novo Nordisk (NYSE:NVO) fell -9% this morning after the pharmaceutical company missed expectations on Wall Street with its 4th quarter results and lowered its outlook for 2017. The Danish company posted profits of 8.7 billion Danish kroner, or $1.26 billion USD, on sales of 29.57 billion kroner for the 3 months ended Dec. 31, for bottom-line growth of […]

Filed Under: Diabetes, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Eli Lilly & Co., Novo Nordisk, Sanofi-Aventis

Price collusion: Insulin makers face class-action lawsuit

January 30, 2017 By Sarah Faulkner

A class-action lawsuit filed in the U.S. District Court of Massachusetts alleges that insulin makers Sanofi (NYSE:SNY), Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY) conspired to raise their list prices to get access to pharmacy benefit managers’ preferred lists, instead of competing with each other based on real market prices. In the last 5 years, the 3 companies […]

Filed Under: Diabetes, Featured, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Eli Lilly & Co., Novo Nordisk, Sanofi-Aventis

Johnson & Johnson to pay $30B for Actelion

January 26, 2017 By Sarah Faulkner

Actelion, Johnson & Johnson

After weeks of exclusive negotiations, Johnson & Johnson (NYSE:JNJ) said on Thursday that it plans to buy Swiss biotech firm Actelion (VTX:ATLN) for $30 billion in an all-cash deal. The companies have reportedly been in talks for months – Sanofi (NYSE:SNY) was also involved in discussions for Actelion, but was sidelined after J&J entered into exclusive negotiations with Actelion last […]

Filed Under: Featured, Mergers & Acquisitions, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson, Sanofi-Aventis

Sanofi’s Suliqua combination therapy approved in European Union

January 18, 2017 By Sarah Faulkner

Sanofi logo

Sanofi (NYSE:SNY) said today that the European Commission granted marketing authorization in Europe for its Suliqua combination product for adults with type II diabetes. The therapy is a fixed-ratio combination of basal insulin glargine and lixisenatide, intended to be used with metformin to improve patients’ glycemic control. Suliqua will be available in 2 pre-filled SoloSTAR pens at […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Regulatory/Compliance, Wall Street Beat Tagged With: Sanofi-Aventis

Nordisk takes a hit from Trump, lawsuit

January 13, 2017 By Sarah Faulkner

Novo Nordisk

Novo Nordisk (NYSE:NVO) shares fell more than 5% yesterday, following a lawsuit alleging that the Danish diabetes giant made misleading earning forecasts and comments from the President-elect regarding drug prices. The securities class action lawsuit against Nordisk also named Eli Lilly (NYSE:LLY), Sanofi (NYSE:SNY) and Merck (NYSE:MRK), claiming that Nordisk’s reported earnings and forecasts were inflated through price fixing for the company’s […]

Filed Under: Diabetes, Featured, Legal News, Wall Street Beat Tagged With: Eli Lilly & Co., Merck, Novo Nordisk, Sanofi-Aventis

Sanofi sues Nordisk over Tresiba marketing claims in U.S.

December 28, 2016 By Sarah Faulkner

Sanofi sues Nordisk over Tresiba marketing claims in U.S.

Sanofi (NYSE:SNY) said yesterday that it is suing competitor Novo Nordisk (NYSE:NVO) for “misleading” marketing materials that claim Sanofi’s insulin drugs Lantus and Toujeo will be “blocked” by U.S. pharmacy benefit manager CVS Caremark in January and that patients should switch to Nordisk’s Tresiba. CVS is replacing both Sanofi’s and Nordisk’s drugs with Eli Lilly’s Basaglar on […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Legal News, Pharmaceuticals, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson, Novo Nordisk, Sanofi-Aventis

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS